Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: George Holt who wrote (1031)	5/17/1998 6:15:00 PM
From: Sr K	Read Replies (1) \| Respond to of 2135

In some of today's articles are the statements: At this time, it is not possible to produce the large quantities of endostatin or angiostatin necessary for human trials. and, from the Chicago Tribune piece: Folkman cautioned, however, that the trial could be delayed by ''unpredictable, imponderable things. For one thing, these proteins are hard to ship. They don't like dry ice. They like minus 20 degrees. It makes it really difficult to move them around.''

To: George Holt who wrote (1031)	5/17/1998 8:38:00 PM
From: StockDoc	Respond to of 2135

These are not news. For those who plan to get excited again the ES/AS data in leukemia cure were published in 1997 (that was when I doubled my ENMD shares). It was news then. I hope the preliminary human study (30 pts) that they'll start soon (probably at Harvard) will not be rushed with some junk product. Remember: manufacturing is the biggest hurdle of AS/ES. If it works in half of 30 terminal pts (I hope they do controlled study), there will be no need for more trials. Trust me. It may take over 8 months to complete a study like that. StockDoc